FOLH1 and metastatic prostate carcinoma: Barbato et al. showed that volume quantification with PSMA PET (using a 40 ml cut-off) can discriminatebetween low versus high burden metastatic prostate cancer, with additional sub-classification of disease extension critical for guiding targeted or systemic therapy [14].